Citations

Clear

1134 citation(s) found for "Yan, Di".

Advancements in Cardiovascular Diagnostics
Fang, Karen L., Huang, Zhi , Lu, Yun , Yao, Yali, Li, Yan , Zhang, Bin

Mayo Clinic

Coronary and Cardiothoracic Critical Care | March 13, 2019 | Volume: No volume available | Issue: No issue available | Pages: 1-19

10.4018/978-1-5225-8185-7.ch001 Get It

The cardiology diagnostic are the methods of identifying current or past heart conditions, which can advise caregivers on patient diagnosis and provide a proper therapy plan, nowadays couple new diagnostic methods have been developed and some of them like radionuclide myocardial perfusion imaging, coronary computed tomography angiogram, cardiac magnetic resonance imaging, intravascular ultrasonography, optical coherence tomography, intravascular thermography, intravascular elastography, and near-infrared spectroscopy have been approved for clinical use. Not only the advanced technologies, the new biomarkers, and genetic markers may provide new potential targets for the diagnosis, therapy, and prevention of heart diseases.
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
Isaac, Gaëlle, Vries, Elisabeth G.E. de , Bogaerts, Jan , Chen, Alice P. , Dancey, Janet, Ford, Robert, Gwyther, Stephen J., Hoekstra, Otto S. , Huang, Erich P. , Liu, Yan , Mandrekar, Sumithra J. , Schwartz, Lawrence H., Shankar, Lalitha , Therasse, Patrick, Group, on behalf of the RECIST Working, de Vries, Elisabeth G E , Litière, Saskia , Lin, Nancy U. , Seymour, Lesley , Group, on behalf of the RECIST Working

Mayo Clinic

Journal of Clinical Oncology | March 12, 2019 | Volume: 37 | Issue: 13 | Pages: 1102-1110

10.1200/jco.18.01100 | PMID 30860949 Get It

PURPOSE The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which leads to concerns about the role of RECIST in evaluating tumor response in trials with TCAs. We investigated the performance of RECIST using a pooled database from 50 clinical trials with at least one TCA. METHODS We examined the impact of the number of target lesions (TLs) on within-patient variability of tumor response. The prognostic effect of TL response (at 12 weeks or on study on the basis of a maximum five TLs) on survival was studied through landmark and time-dependent Cox models adjusted for baseline tumor load, occurrence of new lesions, or unequivocal progression of nontarget disease. RESULTS Data were obtained from 23,259 patients with cancer (36% lung, 28% colorectal, 11% breast, and 25% other); 15,620 received TCAs, predominantly transduction or angiogenesis inhibitors, as a single agent (37%), combined with other TCAs (7%), or as chemotherapy (56%); 28% received chemotherapy only; and 5% received best supportive care or placebo. A total of 17,222 patients contributed to the analyses. Within-patient variability decreased with increasing number of TLs, similarly for TCAs (with/without chemotherapy) and chemotherapy only. Mixed responses occurred proportionally in all treatment classes. Landmark analyses showed an ordinal relationship between percentage change from baseline to 12 weeks and overall survival, and demonstrated a clear distinction between tumor shrinkage and progressive disease according to RECIST. Time-dependent analysis showed no marked improvement in the ability to predict survival on the basis of TL tumor growth compared with nontarget progression or new lesion occurrence, regardless of treatment. Similar results were seen for major tumor types and different classes of TCAs. CONCLUSION This work reinforces that RECIST version 1.1 perform well for response assessment of TCAs.
Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors.
Wilcoxen, Keith, Becker, Marc A., Neff, Christopher, Abkevich, Victor, Jones, Joshua T., Hou, Xiaonan , Wang, Yan , Hartman, Anne‐Renee , AlHilli, Mariam , Gutin, Alexander , Agarwal, Shefali , Timms, Kirsten M. , Neff, Chris, Haluska, Paul

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5532-5532

10.1200/jco.2015.33.15_suppl.5532 Get It

Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.
Yan, Yuqian , Wang, Dejie , Pang, Xiaodong , Ma, Jian , Lin, Dong , Giles, Francis Joseph , Wang, Yuzhuo , Huang, Haojie

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 62-62

10.1200/jco.2019.37.7_suppl.62 Get It

62 Background: We have previously reported that mutations in SPOP promote bromodomain and extra-terminal motif (BET) protein upregulation and BET inhibitor resistance in prostate cancer (Zhang et al., Nature Medicine 23(9):1055-1062, 2017). Other studies indicate that histone acetyltransferases (HATs) such as P300 are also upregulated in SPOP-mutated prostate cancer (Blattner et al., Cancer Cell 31: 436-451, 2017). Methods: We examined the anti-cancer effect of NEO2734 (Epigene Therapeutics Inc), a novel dual inhibitor of both BET and CBP-P300, in prostate cancer using cell line, organoid and patient-derived xenografts (PDX) as working models. We examined the anti-cancer effect of NEO2734 (Epigene Therapeutics Inc), a novel dual inhibitor of both BET and CBP-P300, in prostate cancer using cell line, organoid and patient-derived xenografts (PDX) as working models. Results: We demonstrated that while prostate cancer cell lines expressing F133V, the most frequent SPOP mutant, are very resistant to both BET inhibitor JQ1 and CBP/P300 inhibitor CPI-637, they are very sensitive to simultaneous cotreatment with JQ1 and CPI-637. Similarly, we demonstrated that F133V mutant cells are also very sensitive to NEO2734. We established PDX and organoid models from a patient with prostate cancer expressing a novel SPOP mutation Q165P. Computer simulation analysis reveals that the Q165P mutation causes larger conformational fluctuation, indicating that the structure of Q165P is less stable than that of wild type SPOP. Accordingly, co-immunoprecipitation assay showed that Q165P mutation impaired the dimerization ability of SPOP. We further showed that the Q165P mutant organoid was very sensitive to NEO2734 in vitro and the Q165P mutant PDX was very sensitive to NEO2734 in mice. Conclusions: These PDX-based pre-clinical studies indicate that the inhibition of both BET and CBP-P300, either by co-administration of two agents, or by treatment with the dual inhibitor, NEO2734, is effective in SPOP-mutated prostate cancer. These data provide a strong rationale for the inclusion of patients with SPOP-mutated prostate cancer in clinical studies of NEO2734.
Cardiac hypertrophy and arrhythmia in mice induced by a mutation in ryanodine receptor 2
Alvarado, Francisco , Yuchi, Zhiguang , Valdivia, Carmen R. , Hernández, Jonathan J. , Zhao, Yan-Ting , Henderlong, Dawn S., Booher, Talia R. , Marcou, Cherisse A. , Petegem, Filip Van , Ackerman, Michael J. , Valdivia, Héctor H. , Bos, J. Martijn , Henderlong, Dawn Shirley, Chen, Yan, Booher, Talia

Mayo Clinic

JCI Insight | March 5, 2019 | Volume: 4 | Issue: 7 | Pages: No page available

10.1172/jci.insight.126544 | PMID 30835254 Get It

Hypertrophic cardiomyopathy (HCM) is triggered mainly by mutations in genes encoding sarcomeric proteins, but a significant proportion of patients lack a genetic diagnosis. We identified a potentially novel mutation in ryanodine receptor 2, RyR2-P1124L, in a patient from a genotype-negative HCM cohort. The aim of this study was to determine whether RyR2-P1124L triggers functional and structural alterations in isolated RyR2 channels and whole hearts. We found that P1124L induces significant conformational changes in the SPRY2 domain of RyR2. Recombinant RyR2-P1124L channels displayed a cytosolic loss-of-function phenotype, which contrasted with a higher sensitivity to luminal [Ca 2+ ], indicating a luminal gain of function. Homozygous mice for RyR2-P1124L showed mild cardiac hypertrophy, similar to the human patient. This phenotype, evident at 1 year of age, was accompanied by an increase in the expression of calmodulin (CaM). P1124L mice also showed higher susceptibility to arrhythmia at 8 months of age, before the onset of hypertrophy. RyR2-P1124L has a distinct cytosolic loss-of-function and a luminal gain-of-function phenotype. This bifunctionally divergent behavior triggers arrhythmias and structural cardiac remodeling, and it involves overexpression of CaM as a potential hypertrophic mediator. This study is relevant to continue elucidating the possible causes of genotype-negative HCM and the role of RyR2 in cardiac hypertrophy.
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, Suzanne E. , Li, Yan , Todd, Kaitlin , Herries, Elizabeth, Henson, Rachel L. , Gray, Julia, Wang, Guoqiao , Graham, Danielle , Shaw, Leslie M. , Trojanowski, John Q. , Hassenstab, Jason , Benzinger, Tammie L.S. , Cruchaga, Carlos , Xiong, Chengjie , Chhatwal, Jasmeer P. , Noble, James M. , Ringman, John M. , Graff‐Radford, Neill R. , Ladenson, Jack H., Morris, John C. , Bateman, Randall J. , Fagan, Anne M. , Network, Dominantly Inherited Alzheimer, Fox, Nick C. , Cruchaga, Carlos , Bateman, Randall J , Xiong, Chengjie , Benzinger, Tammie L S , Fox, Nick C , Hassenstab, Jason , Morris, John C , Jucker, Mathias , Holtzman, David M. , Xiong, Chengjie , Network, Dominantly Inherited Alzheimer, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | March 4, 2019 | Volume: 15 | Issue: 5 | Pages: 655-665

10.1016/j.jalz.2018.12.019 | PMID 30846386 Get It

AbstractIntroductionFour less well‐studied but promising “emerging” cerebrospinal fluid (CSF) biomarkers are elevated in late‐onset Alzheimer disease (AD): neurogranin, synaptosomal‐associated protein‐25 (SNAP‐25), visinin‐like protein 1 (VILIP‐1), and chitinase‐3‐like protein 1 (YKL‐40).MethodsCSF neurogranin, SNAP‐25, VILIP‐1, and YKL‐40 were measured in families carrying autosomal‐dominant AD mutations.ResultsThe four emerging CSF biomarkers were significantly elevated in the mutation carriers (n = 235) versus noncarriers (n = 145). CSF SNAP‐25, VILIP‐1, and YKL‐40 were altered very early in the AD time course, approximately 15–19 years before estimated symptom onset. All CSF biomarkers predicted important AD‐related outcomes including performance on a cognitive composite, brain amyloid burden as measured by amyloid positron emission tomography, and the estimated years from symptom onset.DiscussionEarly abnormalities in CSF tTau, pTau, SNAP‐25, VILIP‐1, and YKL‐40 suggest that synaptic damage, neuronal injury, and neuroinflammation begin shortly after the commencement of brain amyloid accumulation.
Host genetic variation in tumor necrosis factor and nuclear factor‐κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study
Wang, Sophia , Sarangi, Vivekananda , Link, Brian K. , Inwards, David J. , Witzig, Thomas E. , Rothman, Nathaniel , Asmann, Yan W. , Witzig, T.E. , Asmann, Yan, Cerhan, James R , Link, Brian K , Wang, Sophia S , Wang, Yucai , Habermann, Thomas M. , Maurer, Matthew J. , Feldman, Andrew L. , Cozen, Wendy , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | February 28, 2019 | Volume: 94 | Issue: 6 | Pages: No page available

10.1002/ajh.25451 | PMID 30815899 Get It

Percutaneous Pedicle Screw Fixation Alone Versus Debridement and Fusion Surgery for the Treatment of Early Spinal Tuberculosis: A Retrospective Cohort Study
Guo, Song , Zhu, Kai , Zhang, Shuya , Yang, Mingjie , Yan, Meijun , Li, Xinhua , Pan, Jie , Li, Lijun , Wang, Zhigang , Tan, Jun , Ma, Bin

Mayo Clinic

Medical Science Monitor | February 27, 2019 | Volume: 25 | Issue: No issue available | Pages: 1549-1557

10.12659/msm.912538 | PMID 30811378 Get It

A Proposal to Add a New Dedicated Chapter in ICD-11: Disorders Related to Chronic Pain
Cheng, Jianguo , Han, Ji-Sheng, Gallagher, Rollin M., Fan, Bifa , Liu, Yanqing , Stanos, Steven P., Lamer, Tim J. , Zhang, Daying , Fu, Zhijian , Yi, Xiaobin , Liu, Xiaoli , Ma, Ke , Jin, Yi, Yang, Xiao-Qiu, Huang, Dong , Xiao, Lizu, Feng, Zhi-Ying, Cheng, Zhixiang , Lü, Yan , Song, Xue‐Jun , Yu, Shengyuan , Jin, Yi, Feng, Zhi-Ying

Mayo Clinic

Pain Medicine | February 27, 2019 | Volume: 21 | Issue: 3 | Pages: 436-438

10.1093/pm/pnz060 | PMID 30953586 Get It

Hydrogels: Multifunctional “Hydrogel Skins” on Diverse Polymers with Arbitrary Shapes (Adv. Mater. 7/2019)
Yu, Yan , Yuk, Hyunwoo , Parada, German Alberto , Wu, You , Liu, Xinyue , Nabzdyk, Christoph S. , Youcef‐Toumi, Kamal , Zang, Jianfeng , Zhao, Xuanhe

Mayo Clinic

Advanced Materials | February 12, 2019 | Volume: 31 | Issue: 7 | Pages: No page available

10.1002/adma.201970044 Get It